gocinirecepti

“You shoot me glances and they’re so hard to read, I misconstrue what you mean. … Are you just playing, making passes? Well, my heart could use some glasses. … Do I read you correctly, I need you directly, Help me with this part, Do I love you? Do I hate you? I got a […]

People with very rapidly progressing familial amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene may gain early access to Biogen’s experimental therapy tofersen by mid-July, the company announced.   This marks the first part of Biogen’s planned access program for tofersen, and will begin after patients initially assigned to a placebo in VALOR, the Phase 3 portion of a

Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.   Amyotrophic lateral sclerosis (ALS) patients require walking aids, ventilation support, and/or speech generation devices about 1.5 years after starting treatment with Radicava (edaravone), according to data from U.S. insurance health claims.  

“Everybody’s talkin’ at me, Can’t hear a word they’re sayin’, Only the echoes of my mind.” – Fred Neil   ALS has rendered me a minimalist creature of habit. My weekday routine includes the intersection of paranoid caution, practiced routine, and hunger — known to most as lunch. During this necessary refueling stage, I often take

Registration is now open for fundraising events at four championship golf courses, whose fees will be used to fund research, care, and advocacy for neuromuscular disorders such as amyotrophic lateral sclerosis (ALS) and muscular dystrophy. According to the Muscular Dystrophy Association (MDA), which is promoting the events, money raised will help to provide equal access

Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference.   WVE-004, an investigational treatment for people with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) who carry C9orf72 gene mutations, lowered the

Under an agreement with the University of Kansas, PharmaTher has gained exclusive worldwide rights to develop and possibly commercialize ketamine as a therapy for amyotrophic lateral sclerosis (ALS). “We are pleased to have added the [ALS] program to our already impressive development pipeline that focuses on novel uses, formulations and delivery of ketamine in the

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder associated with the death of motor neurons. These are nerve cells that control the voluntary muscles, which are essential for movement.   As the condition progresses, the muscles weaken and waste away, resulting in a loss of muscle control. Although ALS can progress differently in each

January 2021: Motor neurone disease treatments that boost energy in nerve cells could be developed thanks to new research. Researchers at the Euan MacDonald Centre for MND Research have recently published the findings of a research study that has provided a new focus for potential drug treatments for MND.   The research team created a